13 July 2015

Consortium reinforces connections with Sub-Saharan Africa

As the development program (currently in clinical phase I) moves into phase II early next year, it will see close collaboration with clinical research centers in Sub-Saharan Africa – the Pediatric Praziquantel Consortium is fully committed to developing closer connections with the region.

The overall Consortium objective is developing and providing a suitable pediatric praziquantel formulation for preschool-aged children suffering from schistosomiasis. The major disease burden lies in Sub-Saharan Africa, and the Consortium has always sought input from key endemic country clinical and regulatory experts, and from international organizations, such as WHO. From the start, stakeholders have been invited to annual expert meetings, to exchange details about their needs and benefit from their expertise.

Meetings to date have focused on the Target Product Profile, the clinical development program and the regulatory strategy. During the clinical development program, close collaboration with leading clinical research centers in Sub-Saharan Africa is the logical next step.